Q-omics provides the consensus-scored PIK3CB profile across patient tissues and cancer cell-line models. PIK3CB expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PIK3CB is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, PIK3CB RNA expression shows 20,083 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where PIK3CB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIK3CB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIK3CB survival associations across molecular data types. PIK3CB RNA expression shows survival associations in the most cancer types (22), followed by mutation status (11) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIK3CB RNA expression–survival associations across cancer types. High PIK3CB expression shows unfavorable associations in PAAD, MESO, LUSC and LIHC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PIK3CB RNA expression.
This table summarizes PIK3CB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PIK3CB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIK3CB shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, STAD, HNSC and BRCA. The LIHC box plot shows higher PIK3CB RNA expression in tumor versus normal tissue (log2 FC = +1.001, t-test p < 0.001).
This table shows molecular features associated with PIK3CB in patient tissues and cancer cell lines. In patient samples, PIK3CB shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PIK3CB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
